
FONDAZIONE GIOVANNI LORENZINI MILAN, ITALY  GIOVANNI LORENZINI MEDICAL FOUNDATION HOUSTON, TX USA

**2nd International Symposium on
TRIGLYCERIDES AND HDL:
ROLE IN CARDIOVASCULAR DISEASE AND
THE METABOLIC SYNDROME**



SCIENTIFIC PROGRAM

NOTE: THE AUTHOR LISTED IN BOLD TYPE IS THE PRESENTING AUTHOR.

WELCOME AND OPENING LECTURE

Chair:

Paoletti R. (Milan, Italy)

Hour:		Abstract Book Page Reference
8:30	HDL AND TRIGLYCERIDES: AN EVOLVING STORY IN CARDIOVASCULAR PREVENTION Gotto A.M., Jr. (New York, NY, USA)	2

PLENARY SESSION 1

THE METABOLIC SYNDROME

Chairs:

Paoletti R. (Milan, Italy)

Gotto A.M., Jr. (New York, NY, USA)

Hour:		Abstract Book Page Reference
9:00	XXXI LORENZINI ANNUAL LECTURE METABOLIC SYNDROME: EPIDEMIOLOGICAL AND GENETIC OVERVIEW Grundy S.M. (Dallas, TX, USA)	2
9:30	ATHEROSCLEROSIS AND THE METABOLIC SYNDROME: UNDERSTANDING BASIC MECHANISMS AND NEW TARGETS Plutzky J. (Boston, MA, USA)	2
10:00	METABOLIC SYNDROME AND CVD: OVERVIEW OF EPIDEMIOLOGY AND CLINICAL TRIALS TO REDUCE ATHEROSCLEROSIS Steiner G. (Toronto, ON, Canada)	2
10:30	<i>End of the Session</i>	
10:30 – 11:00	<i>Coffee Break</i>	

SYMPOSIUM 1

**THE SPECTRUM OF CARDIOVASCULAR RISK:
WHO SHOULD BE TREATED AND WHEN**

Chairs:

Brewer H.B., Jr. (Bethesda, MD, USA)

Grundy S.M. (Dallas, TX, USA)

Hour:		Abstract Book Page Reference
11:00	WELCOME AND PROGRAM INTRODUCTION Brewer H.B., Jr. (Bethesda, MD, USA)	—
11:05	ASSESSMENT AND MANAGEMENT OF PATIENTS WITH METABOLIC SYNDROME AND ABDOMINAL OBESITY Grundy S.M. (Dallas, TX, USA)	3
11:30	WAIST AND TG: SCREENING TOOLS TO DETECT PATIENTS WITH INCREASED ABDOMINAL ADIPOSITY Lamarche B. (Sainte-Foy, QC, Canada)	3
11:55	THE RIO PROGRAM: IMPROVEMENT OF METABOLIC PARAMETERS AND NEW DATA FROM RIO DIABETES Van Gaal L. (Antwerp, Belgium)	3
12:20	PANEL DISCUSSION	—
12:30	<i>End of the Session</i>	
12:30 – 2:00	<i>Break</i>	

*Supported in part by an unrestricted educational grant from
sanofi-aventis*

SYMPOSIUM 2

THE CASE FOR COMBINATION THERAPY IN THE MANAGEMENT OF DYSLIPIDEMIA: A FOCUS ON HDL-C

Chairs:

Ballantyne C.M. (Houston, TX, USA)

Gotto A.M., Jr. (New York, NY, USA)

Hour:		Abstract Book Page Reference
2:00	EMERGING ROLE OF HDL-C: IS THE TIME RIGHT FOR HDL-C GUIDELINES? Gotto A.M., Jr. (New York, NY, USA)	3
2:20	ROLE OF HDL AND ITS SUBFRACTIONS IN CARDIOVASCULAR DISEASE RISK REDUCTION Schaefer E.J., Brousseau M.E., Asztalos B.F. (Boston, MA, USA)	4
2:40	LIPOPROTEIN SUBCLASSES, INFLAMMATION, AND CARDIOVASCULAR RISK IN THE METABOLIC SYNDROME Rosenson R.S. (Chicago, IL, USA)	4
3:00	EVIDENCE TO SUPPORT AGGRESSIVE MANAGEMENT OF HDL-C: IMPLICATIONS OF RECENT TRIALS Taylor A. (Washington, DC, USA)	4
3:20	COMBINATION THERAPY FOR MULTIPLE LIPID DISORDERS: A GLIMPSE INTO THE FUTURE Ballantyne C.M. (Houston, TX, USA)	4
3:40	PANEL DISCUSSION / QUESTION AND ANSWER	—
4:00	<i>End of the Session</i>	
4:00 – 4:30	<i>Coffee Break</i>	

*Supported in part by an unrestricted educational grant from
Kos Pharmaceuticals, Inc.*

WORKSHOP 1

MOLECULAR MECHANISMS AND CLINICAL CONSEQUENCES OF INSULIN RESISTANCE

Chairs:

Capeau J. (Paris, France)

Chait A. (Seattle, WA, USA)

Hour:		Abstract Book Page Reference
2:00	MECHANISMS BY WHICH COMPONENTS OF THE METABOLIC SYNDROME MIGHT IMPACT THE ARTERY WALL Chait A. (Seattle, WA, USA)	5
2:20	INSULIN RESISTANCE: LESSONS FROM HUMAN LIPODYSTROPHIES Capeau J. (Paris, France)	5
2:40	DECIPHERING THE PHENOTYPIC AND GENETIC COMPLEXITY OF METABOLIC SYNDROME Waterworth D.M. , Stirnadel H., Lin X., Ling H., Barter P., Kesaniemi A., Mahley R., McPherson R., Waeber G., Wyszynski D., Farrer L., Mitchell B., Grundy S., Mooser V.E. (Collegeville, PA, Baltimore, MD, San Francisco, CA, Boston, MA and Dallas, TX, USA, Sydney, Australia, Oulu, Finland, Ottawa, ON, Canada and Lausanne, Switzerland)	5
2:55	RELATIONSHIPS BETWEEN CHOLESTERYL ESTER TRANSFER ACTIVITY AND CORONARY RISK FACTORS IN METABOLIC SYNDROME Charlton-Menys V. , Liu Y., Kwok S., Pemberton P.W., Morgan J., Durrington P.N. (Manchester, UK)	5
3:10	HIGH TRIGLYCERIDES, LOW HDL CHOLESTEROL, AND SMALL LDL PARTICLES PREDICT INCIDENT TYPE 2 DIABETES IN NON-DIABETIC CORONARY PATIENTS Aczel S., Saely C.H. , Marte T., Langer P., Schmid F., Koch L., Rein P., Drexel H. (Feldkirch, Austria)	6
3:25	EASILY ASSESSABLE CLINICAL PREDICTORS OF INSULIN RESISTANCE: GEMS AND ADOPT STUDY Patwardhan R. , Lin X., Waterworth D. (King of Prussia, PA, USA)	6
3:40	<i>End of the Session</i>	
3:40 – 4:30	<i>Coffee Break</i>	

WORKSHOP 2

LIPOPROTEIN, HEPATIC, AND ENDOTHELIAL LIPASES

Chairs:

Greten H. (Hamburg, Germany)

Rader D.J. (Philadelphia, PA, USA)

Hour:		Abstract Book Page Reference
2:00	UNUSUAL PATHWAYS OF LIPID UPTAKE BY MUSCLES Goldberg I.J. , Augustus A.S., Yokoyama M. (New York, NY, USA)	6
2:20	UPDATE ON ENDOTHELIAL LIPASE Rader D.J. , Badellino K., Griffon N., Wang X., Jin W., Broedl U., Marchadier D., Glick J., Paradis M., Lamarche B., Plutzky J. (Philadelphia, PA, USA)	6
2:40	ENDOTHELIAL LIPASE: RECOMBINANT EXPRESSION, PURIFICATION AND HTS ASSAY DEVELOPMENT Bellanti B. , Carettoni D. (Milan, Italy)	7
2:55	NOVEL ETHNIC-SPECIFIC ASSOCIATIONS BETWEEN ENDOTHELIAL AND HEPATIC LIPASE POLYMORPHISMS AND NMR HDL SUBCLASSES AND SIZE Miljkovic Gacic I. , Bunker C.H., Ferrell R.E., Kammerer C.M., Evans R.W., Patrick A.L., Kuller L.H. (Pittsburgh, PA, USA and Scarborough, Trinidad & Tobago)	7
3:10	CLINICAL SIGNIFICANCE OF MEASURING LIPOPROTEIN LIPASE (LPL) MASS IN PREHEPARIN PLASMA FOR THE DIAGNOSIS OF LPL ABNORMALITY Ikeda Y. , Takagi A., Nishimura M., Iwanaga T., Ohkaru Y. (Osaka, Japan)	7
3:25	ENDOTHELIAL LIPASE AND LIPOPROTEIN METABOLISM IN HUMAN Paradis M.E. , Rader D.J., Badellino K.O., Couture P., Bergeron N., Lamarche B. (Sainte-Foy, QC, Canada and Philadelphia, PA, USA)	7
3:40	<i>End of the Session</i>	
3:40 – 4:30	<i>Coffee Break</i>	

WORKSHOP 3

DIETARY CONTROVERSIES:
DEBATE ON OPTIMAL TREATMENT OF THE METABOLIC SYNDROME

Chairs:

Paoletti R. (Milan, Italy)

Schaefer E.J. (Boston, MA, USA)

Abstract Book
Page Reference

Hour:		Abstract Book Page Reference
4:30	DIETARY COMPOSITION VERSUS CALORIC RESTRICTION FOR THE TREATMENT OF METABOLIC SYNDROME Schaefer E.J. , Gleason J.A., Dansinger M.L. (Boston, MA, USA)	8
4:50	WHAT IS THE BEST DIET FOR TREATING THE METABOLIC SYNDROME? Klein S. (St. Louis, MO, USA)	8
5:10	COMPARISON OF THE EFFECTS OF POPULAR DIETS ON METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE Samaha F.F. (Philadelphia, PA, USA)	8
5:30	VERY LOW-CARBOHYDRATE DIETS ARE SUPERIOR TO LOW-FAT DIETS FOR TREATING LIPID DISORDERS IN SUBJECTS WITH ELEVATED TRIGLYCERIDES AND LOW HDL CHOLESTEROL Forsythe C.E. , Quann E.E., Wood R.J., Sharman M.J., Silvestre R., Ruffin K.T., Judelson D.A., Yamamoto L.M., Sokmen B., Hatfield D.L., Kraemer W.J., Fernandez M.L., Volek J.S. (Storrs, CT, USA)	8
5:45	DIETARY LONG CHAIN MONOUNSATURATED FATTY ACIDS (LC-MUFA) AND HEXACOSANOIC ACID (C26:0) IN RED BLOOD CELLS, A NEW FACTOR FOR ATHEROSCLEROSIS Oshida K. , Yanagisawa N., Kitamura Y., Li Y., Takase M., Tamura Y., Hayasawa H., Tsukamoto K., Antoku Y. (Zama-City, Japan)	9
6:00	OMEGA - 3 SUPPLEMENTATION ENHANCES BODY FAT LOSS DURING EXERCISE Hill A.M. , Buckley J.D., Murphy K.J., Saint D.A., Howe P.R.C. (Adelaide, Australia)	9
6:15	C-REACTIVE PROTEIN LEVELS PREDICT THE LIPID AND LIPOPROTEIN RESPONSE TO DIETARY INTERVENTIONS Lamarque B. , Desroches S., Archer W.R., Paradis M.E., Dériaz O., Couture P., Bergeron J., Bergeron N. (Sainte-Foy, QC, Canada)	9
6:30	<i>End of the Session</i>	

WORKSHOP 4

NOVEL TARGETS INVOLVING NEURO-HUMORAL REGULATION OF OBESITY AND ADIPOCYTOKINES

Chairs:

de Graaf J. (Nijmegen, The Netherlands)

Leibel R.L. (New York, NY, USA)

Hour:		Abstract Book Page Reference
4:30	METABOLIC CONSEQUENCES OF THERAPEUTIC WEIGHT REDUCTION Rosenbaum M., Leibel R.L. (New York, NY, USA)	9
4:50	DECREASED ADIPONECTIN LEVELS IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA (FCH) PREDICT THE ATHEROGENIC LIPID PROFILE de Graaf J. , van der Vleuten G.M., van Tits L.J.H., den Heijer M., Lemmers H., Stalenhoef A.F.H. (Nijmegen, The Netherlands)	10
5:10	ADIPOCYTE FATTY ACID BINDING PROTEIN (AP2), A NEWLY IDENTIFIED LXR TARGET GENE, IS INDUCED BY LXR AGONISTS IN HUMAN THP-1 CELLS Lui Q.-Y., Quinet E., Nambi P. (Collegeville, PA, USA)	10
5:25	ADIPOSE TISSUE REGULATES PLASMA LIPID LEVELS AND ADIPOSITY VIA FASTING-INDUCED ADIPOSE FACTOR/ ANGIOPOIETIN-LIKE PROTEIN 4 Zandbergen F. , Mandard S., van Straten E., Wahli W., Kuipers F., Müller M., Kersten S. (Wageningen and Groningen, The Netherlands and Lausanne, Switzerland)	10
5:40	ASEX-SPECIFIC DETERMINANTS OF ADIPONECTIN IN OLDER ADULTS: THE ROLE OF SERUM SEX HORMONES Laughlin G.A. , Barrett-Connor E., May S. (La Jolla, CA, USA)	10
5:55	OBESITY, PLASMA HIGH SENSITIVITY C-REACTIVE PROTEIN LEVELS AND INSULIN RESISTANCE STATUS AMONG SCHOOL CHILDREN IN TAIWAN Chu N.-F. , Shen M.-H., Wu D.-M., Wang D.-J. (Taipei, Taiwan)	11
6:10	<i>End of the Session</i>	

PLENARY SESSION 2

MECHANISMS INVOLVING HDL METABOLISM

Chairs:

Sirtori C.R. (Milan, Italy)

Brewer H.B., Jr. (Bethesda, MD, USA)

Hour:		Abstract Book Page Reference
8:30	INCREASING HDL AS AN EMERGING APPROACH TO THE TREATMENT OF CVD Brewer H.B., Jr. (Bethesda, MD, USA)	11
9:00	ROLE OF HIGH DENSITY LIPOPROTEINS IN COMBATING VASCULAR INFLAMMATION Barter P.J. (Sydney, Australia)	11
9:30	HDL THERAPY: MECHANISMS AND CLINICAL POTENTIAL Sirtori C.R. (Milan, Italy)	12
10:00	HDL AND REVERSAL OF MACROPHAGE FOAM CELL FORMATION Tall A.R. (New York, NY, USA)	12
10:30	<i>End of the Session</i>	
10:30 – 11:00	<i>Coffee Break</i>	

SYMPOSIUM 3

INFLAMMATION AND CARDIOVASCULAR DISEASE: IMPACT ON DIAGNOSIS AND PATIENT MANAGEMENT

Chairs:

Paoletti R. (Milan, Italy)
Ridker P.M. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
11:00	WELCOME AND INTRODUCTIONS Ridker P.M. (Boston, MA, USA)	—
11:05	THE ROLE OF hsCRP IN DYSLIPIDEMIA Ridker P.M. (Boston, MA, USA)	12
11:30	CV BIOMARKERS AND CAD PROGRESSION: THE LINK BETWEEN LDL-C, CRP, AND ATHEROSCLEROSIS Nissen S.E. (Cleveland, OH, USA)	12
11:55	ANTI-INFLAMMATORY EFFECTS OF STATINS Ganz P., Liao J.K., (Boston, MA, U.S.A.)	13
12:20	PANEL DISCUSSION AND CLOSING REMARKS Faculty/Ridker P.M., Paoletti R. (Boston, MA, USA and Milan, Italy)	—
12:30	<i>End of the Session</i>	
12:30 – 2:00	<i>Break</i>	

*Supported in part by an unrestricted educational grant from
AstraZeneca Pharmaceuticals, LP*

SYMPOSIUM 4

BEYOND LDL: TREATMENT OPTIONS FOR THE PATIENT AT RISK

Chairs:

Després J.-P. (Sainte-Foy, QC, Canada)

Libby P. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
2:00	WELCOME AND INTRODUCTION Libby P. (Boston, MA, USA)	—
2:10	OPTIMAL MANAGEMENT OF CVD RISK IN PATIENTS WITH TYPE 2 DIABETES AND THE METABOLIC SYNDROME Després J.-P. (Sainte-Foy, QC, Canada)	13
2:35	RATIONALE AND DESIGN FOR A LARGE-SCALE STUDY OF FIBRATE THERAPY IN DIABETES: THE FIELD TRIAL Keech A.C. , Best J.D., Scott R.S., Barter P.J., Simes R.J., Forder P., Taskinen M-R. for the FIELD Study Investigators (Sydney, Australia)	13
3:00	PPAR-ALPHA AGONISTS: MECHANISMS OF ACTION AND PARTICULAR BENEFITS IN PATIENTS WITH TYPE 2 DIABETES AND THE METABOLIC SYNDROME Libby P. (Boston, MA, USA)	13
3:25	ASSESSING THE EFFICACY AND SAFETY OF FIBRATE-STATIN COMBINATION THERAPIES IN THE MANAGEMENT OF HIGH-RISK MIXED DYSLIPIDEMIC PATIENTS Jones P.H. (Houston, TX, USA)	14
3:50	QUESTIONS AND ANSWERS	—
4:00	<i>End of the Session</i>	
4:00 – 4:30	<i>Coffee Break</i>	

*Supported in part by an unrestricted educational grant from
Abbott Laboratories*

WORKSHOP 5
NEW APPROACHES TO HDL

Chairs:

Franceschini G. (Milan, Italy)
Schaefer E.J. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
2:00	CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITION, LIPID METABOLISM AND HEART DISEASE PREVENTION Schaefer E.J. , Asztalos B.F., Brousseau M.E. (Boston, MA, USA)	14
2:20	SYNTHETIC HDL FOR CHD PREVENTION AND TREATMENT Franceschini G. (Milan, Italy)	14
2:40	INFLAMMATION IMPAIRS THE ABILITY OF MOUSE SERUM TO REMOVE CELLULAR LIPIDS BY THE ABCA1 PATHWAY Chiba T. , Vaughan A., Heinecke J., Chait A., Oram J.F. (Seattle, WA, USA)	14
2:55	HIGH-DENSITY LIPOPROTEINS INDUCE TRANSFORMING GROWTH FACTOR BETA 2 EXPRESSION IN ENDOTHELIAL CELLS Norata G.D. , Callegari E., Marchesi M., Chiesa G., Eriksson P., Catapano A.L. (Milan, Italy, Stockholm, Sweden and Cinisello Balsamo, Italy)	15
3:10	PDZK1 C-TERMINAL REGION, NOT DIRECTLY INVOLVED IN SR-BI BINDING, IS REQUIRED FOR UP-REGULATION OF SR-BI EXPRESSION Nakamura T. , Shibata N., Arai H. (Tokyo, Japan)	15
3:25	SELECTIVE MODIFICATION OF HDL APOLIPOPROTEIN COMPOSITION BY CONJUGATED LINOLEIC ACID ISOMERS IN APOLIPOPROTEIN E KNOCKOUT MICE Arbonés-Mainar J.M., Navarro M.A., Guzmán M.A., Surra J.C., Acín S., Arnal C., Carnicer R., Roche H.M., Osada J. (Zaragoza, Spain and Dublin, Ireland)	15
3:40	THERAPEUTIC INTERVENTIONS INTENDED TO PREVENT THE PROGRESSION OF ACUTE CORONARY SYNDROME USING RECONSTITUTED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL Miura S. , Uehara Y., Imaizumi S., Kiya Y., Lye K.A., Saku K. (Fukuoka, Japan and Sydney, Australia)	15
3:55	<i>End of the Session</i>	
3:55 – 4:30	<i>Coffee Break</i>	

*Supported in part by an unrestricted educational grant from
Pfizer Inc. and Esperion Therapeutics, A Division of Pfizer Global Research & Development*

WORKSHOP 6

TARGETING TRANSCRIPTIONAL REGULATION AS THERAPY:
PPARS AND OTHER APPROACHES

Chairs:

Staels B. (Lille, France)

Yki-Järvinen H. (Helsinki, Finland)

Hour:		Abstract Book Page Reference
2:00	NUCLEAR RECEPTORS MODULATING THE METABOLIC SYNDROME: FOCUS ON PPAR α AND FXR Staels B. (Lille, France)	16
2:20	MECHANISM OF ACTION OF PPAR γ AGONISTS IN HUMANS Yki-Järvinen H. (Helsinki, Finland)	16
2:40	A CELL BASED ASSAY PLATFORM FOR THE HIGH THROUGHPUT SCREENING OF LIGAND GATED TRANSCRIPTION FACTORS AGONISTS De Silvestris M. , Agus V., Redaelli L., Piazza G., Arioli P., Blasi K., Scarabottolo L. (Milan, Italy)	16
2:55	LXR β REGULATION IN LXR α DEFICIENT MICE: IMPLICATIONS FOR THERAPEUTIC TARGETING Quinet E.M. , Savio D.A., Halpern A.R., Schuster G.U., Gustafsson J.-A., Nambi P. (Collegeville, PA, USA and Huddinge, Sweden)	16
3:10	THERAPEUTIC SILENCING OF APOB BY SYSTEMIC DELIVERY OF SHORT INTERFERING RNAs Soutschek J. , Koteliensky V., Vornlocher H.-P. (Kulmbach, Germany and Cambridge, MA, USA)	17
3:25	INFLUENCE OF THE COMMON POLYMORPHISMS ON THE TREATMENT OF METABOLIC SYNDROME Dzgoeva F. , Larionova V., Glazkov P. (Moscow and St. Petersburg, Russia)	17
3:40	APOLIPOPROTEIN A5 ACCELERATES PLASMA HYDROLYSIS OF TRIGLYCERIDE-RICH LIPOPROTEINS BY INTERACTION WITH PROTEOGLYCAN BOUND LIPOPROTEIN LIPASE Merkel M. , Pennacchio L.A., Heeren J. (Hamburg, Germany)	17
3:55	<i>End of the Session</i>	
3:55 – 4:30	<i>Coffee Break</i>	

SYMPOSIUM 5

TRIGLYCERIDES AND THE METABOLIC SYNDROME:
NEW INSIGHTS AND OPTIONS

Chairs:

Chapman M.J. (Paris, France)

Nakaya N. (Tokyo, Japan)

Hour:		Abstract Book Page Reference
4:30	OPENING REMARKS Nakaya N. (Tokyo, Japan)	—
4:35	AN OVERVIEW OF RECENT ARTICLES ON TRIGLYCERIDES AND METABOLIC SYNDROME Davignon J. (Montreal, QC, Canada)	17
4:55	ADIPOCYTE LIPOLYSIS AND THE METABOLIC SYNDROME Ishibashi S. (Tochigi, Japan)	18
5:15	HIGH DENSITY LIPOPROTEINS IN METABOLIC SYNDROME: THE RELEVANCE OF TRIGLYCERIDE METABOLISM Kontush A., Chapman M.J. (Paris, France)	18
5:35	RELATIONSHIP BETWEEN TRIGLYCERIDE-RICH LIPOPROTEINS AND HDL Welty F.K. (Boston, MA, USA)	18
5:55	TRIGLYCERIDE-RICH LIPOPROTEINS AND ENDOTHELIAL FUNCTION Catapano A.L. (Milan, Italy)	18
6:15	CLOSING REMARKS Chapman M.J. (Paris, France)	—
6:30	<i>End of the Session</i>	

*Supported in part by an unrestricted educational grant from
Kowa Company, Ltd.*

WORKSHOP 7

POTENTIAL BENEFITS OF NOVEL DYSLIPIDEMIA TREATMENTS ON PATIENT OUTCOMES

Chairs:

Packard C.J. (Glasgow, UK)
Brown W.V. (Atlanta, GA, USA)

Hour:		Abstract Book Page Reference
4:30	TREATING LOW HDL-C AND THE CONSEQUENCES FOR LIPOPROTEIN FUNCTIONALITY AND CHD RISK Packard C.J. , Sattar N., Shepherd J. (Glasgow, UK)	19
4:50	IS THE APPROPRIATE TARGET HDL OR TRIGLYCERIDES TO REDUCE EVENTS AND HOW DO WE GET THERE IN PATIENTS Brown W.V. (Atlanta, GA, USA)	19
5:10	HDL ELEVATION THROUGH CETP INHIBITION: ANTI ATHEROGENIC? Kastelein J.J.P. (Amsterdam, The Netherlands)	19
5:30	A NOVEL CELLULAR PHENOTYPE OF MACROPHAGES WITH DEFICIENCY OF ATP-BINDING CASSETTE TRANSPORTER-A1 (ABCA1) Koseki M. , Hirano K., Masuda D., Zhang Z., Ikegami C., Nakagawa-Toyama Y., Shimada Y., Ohno-Iwashita Y., Sato S.B., Kobayashi T., Shimomura I., Yamashita S. (Osaka, Tokyo and Kyoto, Japan)	19
5:45	DOES GENETIC VARIATION IN <i>ABC TRANSPORTER A1</i> PREDICT ISCHEMIC HEART DISEASE IN THE GENERAL POPULATION? Frikke-Schmidt R. , Tybjærg-Hansen A. (Copenhagen, Denmark)	20
6:00	RELATIONSHIP BETWEEN THE LEVELS OF ENDOTHELIAL PROGENITOR CELLS TO HDL-CHOLESTEROL IN PATIENTS WITH CEREBROVASCULAR DISEASE Shuaib U., Salam A., Jeerakathil T., Ghani U., Nasser A.M., Schwindt B., Todd K., Shuaib A. (Edmonton, AB, Canada)	20
6:15	EFFECTS OF SECOND GENERATION ANTIPSYCHOTIC DRUGS ON TRIGLYCERIDES, HDL, AND RELATED LIPIDS IN PATIENTS WITH SCHIZOPHRENIA Smith R.C. , Lindenmayer J.P., Buga A., Kelly E., Matute M., Vaidhyanathaswamy S., Bark N. (New York and Bronx, NY, USA)	20
6:30	<i>End of the Session</i>	

*Supported in part by an unrestricted educational grant from
F. Hoffman-La Roche Ltd.*

WORKSHOP 8

MANAGEMENT OF HYPERTRIGLYCERIDEMIA AND FAMILIAL COMBINED HYPERLIPIDEMIA: A PRACTICAL APPROACH TO DIFFICULT PATIENTS: CASE STUDIES

Chairs:

Vaughan C. (Cork, Ireland)

Faculty from the Weill Medical College of Cornell University:

Vaughan C. (Cork, Ireland)

Roach K. (New York, NY, USA)

Levy C. (New York, NY, USA)

Gordon B. (New York, NY, USA)

Jones E. (New York, NY, USA)

Hour:		Abstract Book Page Reference
4:30	WELCOME AND INTRODUCTION Vaughan C. (Cork, Ireland)	—
4:35	PRIMARY CARE Roach K. (New York, NY, USA)	—
5:00	DIABETES MELLITUS AND INSULIN RESISTANCE Levy C. (New York, NY, USA)	—
5:25	HEART DISEASE AND THE METABOLIC SYNDROME IN WOMEN Jones E. (New York, NY, USA)	—
5:50	OTHER TG CASES Gordon B. (New York, NY, USA)	—
6:15	AUDIENCE CASES Vaughan C. (Cork, Ireland)	—
6:30	<i>End of the Session</i>	

PLENARY SESSION 3

MECHANISMS INVOLVING FREE FATTY ACIDS AND TRIGLYCERIDES

Chairs:

Davignon J. (Montreal, QC, Canada)

Goldberg I. (New York, NY, USA)

Hour:		Abstract Book Page Reference
8:30	GENE REGULATION AT THE MOLECULAR LEVEL BY PPAR ALPHA AND GAMMA Fruchart J.-C. (Lille, France)	20
9:00	ROLE OF REGIONAL FAT IN SPLANCHNIC AND SYSTEMIC FFA METABOLISM Jensen M.D. (Rochester, MN, USA)	21
9:30	THE ROLE OF PPAR GAMMA IN FATTY LIVER AND VLDL SECRETION Ginsberg H. (New York, NY, USA)	21
10:00	LINKS BETWEEN ADIPOSE TISSUE AND VLDL SECRETION Frayn K.N. (Oxford, UK)	21
10:30	<i>End of the Session</i>	
10:30 – 11:00	<i>Coffee Break</i>	

SYMPOSIUM 6

**ATHEROGENIC DYSLIPIDEMIA:
NEW APPROACHES, NEW PERSPECTIVES**

Chairs:

Fruchart J.-C. (Lille, France)

Ginsberg H. (New York, NY, USA)

Hour:		Abstract Book Page Reference
2:00	INTRODUCTION Fruchart J.-C. (Lille, France)	—
2:05	PATHOGENESIS AND ASSESSMENT OF CARDIOVASCULAR RISK IN THE METABOLIC SYNDROME Krauss R.M. (Oakland, CA, USA)	21
2:30	ATHEROGENIC DYSLIPIDEMIA: CHARACTERISTICS AND TREATMENT IN PATIENTS WITH DIABETES Ginsberg H. (New York, NY, USA)	22
2:55	MECHANISM OF PPAR ALPHA AND GAMMA ACTION IN THE MODULATION OF INFLAMMATORY PROCESS AND IN ATHEROSCLEROSIS Fruchart J.-C. (Lille, France)	22
3:20	FUTURE OPTIONS IN THE MANAGEMENT OF DIABETIC PATIENTS WITH DYSLIPIDEMIA: ROLE OF THE DUAL ALPHA-GAMMA PPAR ACTIVATORS DeFronzo R.A. (San Antonio, TX, USA)	22
3:45	PANEL DISCUSSION / QUESTION AND ANSWER SESSION	—
4:00	<i>End of the Session</i>	
4:00 – 4:30	<i>Coffee Break</i>	

*Supported in part by an unrestricted educational grant from
Bristol-Myers Squibb Company and Merck & Co., Inc.*

WORKSHOP 9

POSTPRANDIAL LIPEMIA AND REMNANTS

Chairs:

Catapano A.L. (Milan, Italy)
Sacks F.M. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
2:00	POSTPRANDIAL LIPOPROTEINS AND ENDOTHELIAL DYSFUNCTION. IN VITRO AND IN VIVO STUDIES Catapano A.L., Norata G.D. (Milan and Cinisello Balsamo, Italy)	22
2:20	PROMINENT APO B LIPOPROTEIN PARTICLE TYPES DURING POSTPRANDIAL LIPEMIA Sacks F.M. (Boston, MA, USA)	23
2:40	ACCELERATED INTESTINAL ABSORPTION OF DIETARY LIPIDS CAUSES POSTPRANDIAL HYPERTRIGLYCERIDEMIA IN CD36 KNOCKOUT MICE Masuda D. , Hirano K., Kuwasako T., Ikegami C., Koseki M., Nakagawa- Toyama Y., Zhang Z., Shimomura I., Yamashita S. (Osaka, Japan)	23
2:55	APO A-II IMPAIRS CHYLOMICRON CATABOLISM AND PROVOKES POSTPRANDIAL HYPERTRIGLYCERIDEMIA Dugué-Pujol S., Pastier D., Rousset X., Tran Quang N., Chambaz J., Chabert M., Kalopissis A.D. (Paris, France)	23
3:10	POSTPRANDIAL BUT NOT POSTABSORPTIVE LOW-DENSITY LIPOPROTEINS UPREGULATE THE EXPRESSION OF INTERCELLULAR ADHESION MOLECULE-1 IN HUMAN AORTIC ENDOTHELIAL CELLS Marschang P. , Götsch C., Kirchmair R., Kaser S., Kähler C.M., Patsch J.R. (Innsbruck, Austria)	23
3:25	ELEVATED REMNANT-LIKE PARTICLES CHOLESTEROL LEVELS (RLP-C) IN FAMILIAL COMBINED HYPERLIPIDEMIA de Graaf J. , van der Vleuten G.M., ter Avest E., Dallinga-Thie G., Stalenhoef A.F.H. (Nijmegen and Rotterdam, The Netherlands)	24
3:40	GREATER INCREASE IN POSTPRANDIAL SERUM TRIGLYCERIDES AND OXIDATIVE STRESS AFTER CONSUMPTION OF FISH OIL IN COMPARISON TO SOY OR OLIVE OIL IN MICE: POSSIBLE ROLE FOR PARAOXONASE 1 (PON1) TRIGLYCERIDE LIPASE-LIKE ACTIVITY Fuhrman B. , Volkova N., Aviram M. (Haifa, Israel)	24
3:55	POSTPRANDIAL LIPEMIA INDUCES INSULIN RESISTANCE INDEPENDENTLY OF NON-ESTERIFIED FATTY ACID PLASMA LEVELS Pedrini M.T. , Niederwanger A., Kranebitter M., Tautermann C., Patsch J.R. (Innsbruck, Austria and Oxford, UK)	24
4:10	<i>End of the Session</i>	
4:10 – 4:30	<i>Coffee Break</i>	

WORKSHOP 10

TREATMENT APPROACHES BEYOND STATINS

Chairs:

Jenkins D.J.A. (Toronto, ON, Canada)

Knopp R.H. (Seattle, WA, USA)

Hour:		Abstract Book Page Reference
2:00	METABOLIC BENEFITS OF COMBINED DIETARY INTERVENTIONS: DIETARY PORTFOLIO Jenkins D.J.A. (Toronto, ON, Canada)	24
2:20	NON-STATIN APPROACHES TO TREATING TG/HDL Knopp R.H. (Seattle, WA, USA)	25
2:40	EFFECTS OF CONCENTRIC AND ECCENTRIC MUSCLE EXERCISE ON LIPID AND GLUCOSE METABOLISM IN HEALTHY SEDENTARY INDIVIDUALS Drexel H., Saely C.H. , Loruenser G., Langer P., Marte T., Aczel S. (Feldkirch, Austria)	25
2:55	IMPROVEMENT OF ENDOTHELIUM-DEPENDENT VASODILATION BY SIMVASTATIN IS FACILITATED BY COMBINATION WITH L-ARGININE IN PATIENTS WITH ELEVATED ADMA LEVELS Schulze F. , Böger G.I., Maas R., Schwedhelm E., Bierend A., Benndorf R.A., Böger R.H. (Hamburg, Germany)	25
3:10	MD-0727 IS A MINIMALLY ABSORBED INTESTINAL CHOLESTEROL ABSORPTION INHIBITOR Currie M. , Antonelli S., Barden T., Bartolini W., Bryant A., Busby R., Cali B., Chien Y., Cordero E., Graul C., Hill S., Lee P., Milne T., Lundrigan- Soucy R., Martinez E., Pearson J., Schairer W., Sykes K., Talley J., Weidert T., Yang J.-J., Zimmer D. (Cambridge, MA, USA)	25
3:25	COMBINED THERAPY WITH OMEGA-3 FATTY ACIDS AND NIACIN IN ATHEROGENIC DYSLIPIDEMIA Harris W.S. , Isley W.L., Miles J.M. (Kansas City, MO and Rochester, MN, USA)	26
3:40	ONCE-DAILY EXTENDED-RELEASE NIACIN/LOVASTATIN COMBINATION IMPROVES CHOLESTEROL AND APOLIPOPROTEIN RATIOS COMPARED WITH ATORVASTATIN AND SIMVASTATIN Bays H.E. , Stanek E.J., McGovern M.E. (Louisville, KY and Weston, FL, USA)	26
3:55	<i>End of the Session</i>	
3:55 – 4:30	<i>Coffee Break</i>	

WORKSHOP 11

DRUG TREATMENT TO REDUCE CVD RISK
IN THE METABOLIC SYNDROME

Chairs:

Davidson M.H. (Chicago, IL, USA)

Ganz P. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
4:30	MANAGEMENT OF METABOLIC SYNDROME: BEYOND CHOLESTEROL LOWERING Ganz P. (Boston, MA, USA)	26
4:50	SAFETY CONSIDERATIONS FOR COMBINATION THERAPY FOR PATIENTS WITH METABOLIC SYNDROME Davidson M.H. (Chicago, IL, USA)	26
5:10	WEIGHT LOSS INDEPENDENT EFFECT OF RIMONABANT ON HDL-C AND TRIGLYCERIDE LEVELS IN A 2-YEAR RANDOMIZED CONTROLLED TRIAL Aronne L.J., Pi-Sunyer F.X. (New York, NY, USA)	27
5:25	AHA-RECOMMENDED INTAKES OF OMEGA-3 FATTY ACIDS IMPROVE CARDIAC AUTONOMIC TONE BUT DO NOT REDUCE LIPIDS OR INFLAMMATORY MARKERS Harris W. , Abuissa H., Sastre A., Steinhaus D., O'Keefe J., Jr. (Kansas City, MO, USA)	27
5:40	LIPID-INDEPENDENT EFFECTS OF STATINS ON ENDOTHELIAL FUNCTION AND LEFT VENTRICULAR MASS IN HYPERTENSIVE-TREATED PATIENTS WITH METABOLIC SYNDROME Batista M.C. , Buffani A., Kohlmann O., Jr., Zanella M.T., Ribeiro A.B., Tavares A. (São Paulo, Brazil)	27
5:55	EFFECT OF TREATMENT WITH SIMVASTATIN PLUS FENOFIBRATE ON TRIGLYCERIDE-RICH LIPOPROTEIN PROFILE IN PATIENTS WITH AND WITHOUT THE METABOLIC SYNDROME Grundy S.M., Vega G.L., Yuan Z., Gazzara R.A., Palmisano J. (Dallas, TX and West Point, PA, USA)	27
6:10	<i>End of the Session</i>	

*Supported in part by an unrestricted educational grant from
Merck & Co., Inc.*

WORKSHOP 12

TRIGLYCERIDE-RICH LIPOPROTEINS, INFLAMMATION, AND ATHEROSCLEROSIS

Chairs:

Ceska R. (Prague, Czech Republic)

Hajjar D.P. (New York, NY, USA)

Hour:		Abstract Book Page Reference
4:30	ROLE OF PITAVASTATIN IN ARTERIAL CHOLESTEROL TRAFFICKING Hajjar D.P. , Han J., Nicholson A.C., Parsons M., Zhou X., Gotto A.M., Jr. (New York, NY, USA)	28
4:50	ELECTRONEGATIVE TG-ENRICHED LDL AND VASCULAR INFLAMMATION Abe Y. , Fornage M., Yang C.-Y., Thanh N.-A.B., Wise V., Chen H.-H., Rangaraj G., Ballantyne C.M. (Houston, TX, USA)	28
5:10	ALTERED DNA METHYLATION PATTERNS IN APOE NULL MICE: DIRECT EFFECTS OF PLASMA LIPIDS ON EPIGENETIC PARAMETERS? Lindholm M.W. , Lund G., Esteller M., Nilsson J., Zaina S. (Malmö and Lund, Sweden, Copenhagen, Denmark and Madrid, Spain)	28
5:25	APOLIPOPROTEIN C-III ISOFORMS: KINETICS AND RELATIVE IMPLICATION IN LIPOPROTEIN-LIPID METABOLISM Mauger J.F. , Paradis M.E., Bergeron N., Couture P., Lamarche B. (Sainte- Foy, QC, Canada)	28
5:40	EFFECT OF OXIDIZED HIGH DENSITY LIPOPROTEIN ON LYMPHOCYTE FUNCTION Thies F. , Neo J., Ogilvie R., Lu W. (Aberdeen, UK)	29
5:55	USING TRIGLYCERIDE LEVELS AT ESTABLISHED CUT-OFFS LEADS TO UNDER DIAGNOSIS OF INSULIN RESISTANCE IN NONHISPANIC BLACKS Sumner A.E. , Cowie C.C. (Bethesda, MD, USA)	29
6:10	DECREASED LIPOPROTEIN LIPASE (LPL) ACTIVITY AND DELAYED POSTPRANDIAL CLEARANCE OF TRIGLYCERIDE-RICH LIPOPROTEINS (TRL) IN PERSONS WITH ECHOLUCENT CAROTID PLAQUES Notoe A.T.W. , Mathiesen E.B., Hansen J.B. (Tromsø, Norway)	29
6:25	<i>End of the Session</i>	

WORKSHOP 13

FATTY ACID METABOLISM AND TREATMENT OF
HYPERTRIGLYCERIDEMIA

Chairs:

Galli C. (Milan, Italy)

Lin J. (Boston, MA, USA)

Abstract Book
Page Reference

Hour:

4:30	<p>FATTY ACID PROFILES AND INTERACTIONS IN CIRCULATING LIPIDS IN DEFINING STRATEGIES FOR DIETARY STUDIES IN POPULATION GROUPS Risé P., Marangoni F., Visioli F., Galli C. (Milan, Italy)</p>	29
4:50	<p>CONTROL OF LIPID METABOLISM THROUGH TRANSCRIPTIONAL COACTIVATORS Lin J., Yang R., Newgard C.B., Spiegelman B.M. (Boston, MA, USA)</p>	30
5:10	<p>CONTRIBUTION OF DIETARY FAT TO PLASMA FREE FATTY ACIDS DURING MEAL ABSORPTION Nelson R.H., Roesner J., Russel-Lopez C., Miles J.M. (Rochester, MN, USA)</p>	30
5:25	<p>RELATIONSHIP BETWEEN POSTPRANDIAL FREE FATTY ACIDS AND TRIGLYCERIDES IN NORMAL, DYSLIPIDEMIC AND TYPE 2 DIABETIC SUBJECTS Miles J.M., Isley W.L., Harris W.S. (Rochester, MN and Kansas City, MO, USA)</p>	30
5:40	<p>FAMILIAL CORRELATION, HERITABILITY AND RECURRENT RISKS FOR METABOLIC SYNDROME AND LIPID PROFILES IN TAIWAN CHINESE Chien K.L., Hsu H.C., Su T.C., Lee C.M., Lee Y.T. (Taipei, Taiwan)</p>	30
5:55	<p>FENOFIBRATE (FENOFIBRIC ACID) EXPOSURE AND MAGNITUDE OF TRIGLYCERIDE (TG) RESPONSE FROM NHLBI SPONSORED GENETICS OF LIPID LOWERING DRUGS AND DIET NETWORK (GOLDN) STUDY Straka R.J., Burkhardt R.T., Tsai M., Peacock J.M., Stephenson S.H., Hopkins P.M., Staels B., Arnett D.K. (Minneapolis, MN, Salt Lake City, UT and Birmingham, AL, USA and Lille, France)</p>	31
6:10	<p>EFFECTS OF PIOGLITAZONE IN FAMILIAL COMBINED HYPERLIPIDEMIA (FCH) de Graaf J., Abbink E.J., de Haan J.H., Heerschap A., Stalenhoef A.F.H., Tack C.J. (Nijmegen, The Netherlands)</p>	31
6:25	<i>End of the Session</i>	

PLENARY SESSION 4

ADIPOSE TISSUE: A NEW TARGET FOR
CVD AND TYPE 2 DIABETES PREVENTION

Chairs:

Matsuzawa Y. (Osaka, Japan)

Horton E.S. (Boston, MA, USA)

Hour:		Abstract Book Page Reference
8:30	EFFECTS OF LIFESTYLE MODIFICATION ON ENDOTHELIAL DYSFUNCTION AND CVD RISK FACTORS IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES MELLITUS Horton E.S. (Boston, MA, USA)	31
9:00	ADIPOSE TISSUE: A NEW TARGET FOR CARDIOVASCULAR DISEASE AND METABOLIC DISEASES. ADIPONECTIN AND OBESITY-RELATED DISEASES Matsuzawa Y. (Osaka, Japan)	31
9:30	FAT DOES TALK TO THE ENDOTHELIUM Hsueh W. (Los Angeles, CA, USA)	32
10:00	ABDOMINAL OBESITY: AN IMPORTANT TARGET FOR THE OPTIMAL PREVENTION OF CVD Després J.-P. (Sainte-Foy, QC, Canada)	32
10:30	<i>End of the Session</i>	
10:30 – 11:00	<i>Coffee Break</i>	

PLENARY SESSION 5

CLINICAL TRIALS TO PREVENT TYPE 2 DIABETES

Chairs:

Zinman B. (Toronto, ON, Canada)

Pi-Sunyer F.X. (New York, NY, USA)

Hour:		Abstract Book Page Reference
11:00	<u>DIABETES REDUCTION ASSESSMENT WITH RAMIPRIL AND ROSIGLITAZONE MEDICATIONS: THE DREAM TRIAL</u> Zinman B. (Toronto, ON, Canada)	32
11:30	THE IMPACT OF DIABETES PREVENTION ON CVD RISK Ratner R. (Bethesda, MD, USA)	32
12:00	THE EFFECT OF WEIGHT LOSS ON THE METABOLIC SYNDROME: BEHAVIORAL STUDIES Pi-Sunyer F.X. (New York, NY, USA)	33
12:30	<i>End of the Session</i>	